Taysha Gene Therapies (TSHA) Income towards Parent Company (2022 - 2025)
Historic Income towards Parent Company for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$30.9 million.
- Taysha Gene Therapies' Income towards Parent Company fell 2962.42% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 1565.51%. This contributed to the annual value of -$84.6 million for FY2024, which is 1456.17% down from last year.
- According to the latest figures from Q3 2025, Taysha Gene Therapies' Income towards Parent Company is -$30.9 million, which was down 2962.42% from -$24.9 million recorded in Q2 2025.
- Taysha Gene Therapies' 5-year Income towards Parent Company high stood at -$15.0 million for Q4 2023, and its period low was -$55.1 million during Q4 2022.
- Its 4-year average for Income towards Parent Company is -$26.7 million, with a median of -$23.8 million in 2024.
- As far as peak fluctuations go, Taysha Gene Therapies' Income towards Parent Company skyrocketed by 7269.39% in 2023, and later plummeted by 4336.02% in 2024.
- Taysha Gene Therapies' Income towards Parent Company (Quarter) stood at -$55.1 million in 2022, then surged by 72.69% to -$15.0 million in 2023, then fell by 21.39% to -$18.3 million in 2024, then plummeted by 69.11% to -$30.9 million in 2025.
- Its last three reported values are -$30.9 million in Q3 2025, -$24.9 million for Q2 2025, and -$20.1 million during Q1 2025.